Cancer Vaccine Trial Shows Reduced Melanoma Risk
Moderna and Merck reported that their personalized mRNA cancer vaccine reduced the risk of melanoma recurrence by 42% compared to standard treatment in a clinical trial. The results were described as a significant advancement in personalized cancer treatment.
Confirmed by several outlets
- The vaccine reduced the risk of melanoma recurrence by 42% compared to standard treatment. — STAT and Ars Technica
- The trial is considered significant in the field of personalized cancer treatment. — The Guardian, BBC News and CNBC
Reported by one outlet so far
- The vaccine reduced the risk of disease recurrence and death by 42%. — Ars Technica
- The vaccine results could mark a turning point in cancer treatment, bringing personalized medicine a step closer. — BBC News
- Scientists are studying cancer vaccines for other types of cancer beyond melanoma. — NYT Health
ImpactTop story 61/100
Coverage9 outlets in 3 countries within 21 hours
First reportedSTAT, Thu, 22 Oct 2026 19:03:31 GMT
Who reported it
How this page was made
This page was written automatically. An AI model wrote the headline, summary and lists from the headlines and short extracts of the outlets above. A second AI model then checked every statement against each outlet it is credited to; what it could not confirm was removed, and a page with a statement no outlet supports is not published. For the full story, read the outlets' own reports. See our editorial policy or report a mistake.